Antiparasitic compounds

Abstract

The present invention provides cyclopropylamide compounds useful for treating parasitic infestations in animals. The compound is represented by formula (I): [Formula 1] TIFF2024505500000506.tif74155

Description

[Technical Field]

[0001] The present invention relates to the use of cyclopropylamide compounds to control parasitic infestations in animals. Uses, compositions and methods. [Background technology]

[0002] Many parasites are known to infect animals. These parasites are responsible for the survival of animals and their It can be extremely troublesome for both the owner and the pet owner.

[0003] Therefore, there are many methods for preventing infestations by parasites or for controlling these parasites (especially those used in animals). To reduce or control the proliferation of parasites, such as ticks, in animals. Therefore, animal treatment is important.

[0004] Currently available for controlling parasites, especially ectoparasites and ticks. A suitable compound does not necessarily exhibit good potency, a sufficiently rapid onset of activity, or a long duration of action. That's not the case.

[0005] Ectoparasites tend to infest animals and can be transmitted by themselves or by vectors. by carrying vector-transmitted pathogens This may result in clinical disease or adverse subclinical symptoms.

[0006] In particular, ticks parasitize wild animals, livestock and humans, and are known to transmit bacteria, viruses and known or suspected to be responsible for the transmission of pathogens, such as parasitic protozoa Ticks also release toxins that cause inflammation and paralysis in the host. These toxins are lethal to the host.

[0007] On the other hand, such ectoparasites can have a detrimental effect on the skin by reducing weight gain and milk production. , by causing deterioration of wool and meat and in some cases causing death. This has a serious impact on the productivity of livestock farming. They are also partly responsible for the spread of pathogens as a result of their role in causing discomfort and discomfort to livestock and companion animals. Affects the health of things.

[0008] For example, parasites prevalent among cattle and other livestock include the Rhizobium sanguineum (Rhizobium sanguineum). ephalus ticks, especially R. microplus (tr optical cattle tick), R. decoloratus species (R. decolor atus and R. annulatus species. Ixodes microplus (formerly Boophilus microplus) Ticks such as Ixodes spp. are difficult to control because they lay their eggs in the pastures where animals graze.

[0009] Such limitations include the toxicity of existing compounds to both animals and users / owners. and safety, limited efficacy (potency, onset and duration of activity), narrow spectrum of parasiticidal action These include spectrum, bioavailability, pharmacokinetic and pharmacodynamic issues, and resistance issues. Furthermore, certain aspects of the present invention address the current parasiticide use problems, particularly in those cases where treatment is difficult. Current status in providing effective, long-term, and safe control of parasites that are known to be difficult to treat. This overcomes at least some of the limitations in the use of current parasiticides.

[0010] International patent applications WO2016 / 168056, WO2016 / 168058, WO201 6 / 168059 and WO2018 / 071327 have insecticidal and acaricidal activity, Accordingly, certain cyclopropylamide compounds are disclosed that are useful in controlling agricultural plant pests. Although veterinary use is briefly mentioned, none of these references This also addresses at least some of the needs for using such compounds as veterinary medicines. The use of the compounds claimed herein to address the Furthermore, only a small selection of the compounds described in these references It has been found that only compounds are actually effective against veterinary parasites. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] WO2016 / 168056 [Patent Document 2] WO2016 / 168058 [Patent Document 3] WO2016 / 168059 [Patent Document 4] WO2018 / 071327 Summary of the Invention [Means for solving the problem]

[0012] In a first aspect, the present invention provides a compound of formula (I) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Regarding compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers , Here, in the above formula, A1 is CR 5, where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 1 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of: silyl-S(O)2NH2; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10, NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 11 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0013] Suitably, the compounds of the present invention and any embodiment thereof are useful for treating parasitic infestations in animals. or for use in a method for controlling pests.

[0014] Suitably, compounds and uses according to the present invention and / or any embodiment thereof R 1is selected from the group consisting of HF and Cl; R 2 is selected from the group consisting of H, F and Cl; R 3 is selected from the group consisting of H, F and Cl; R 4 is selected from the group consisting of H, F and Cl; R 5 is selected from the group consisting of HF, Cl, Br, and I; R 6 is selected from the group consisting of H, F and Cl, Br and CH3; R 7 is selected from the group consisting of HF, Cl, Br, and I; R 8 is selected from the group consisting of H, F, Cl, Br and CH3; R 9 is selected from the group consisting of HF, Cl, Br, and I; R 11 is H; R 12 is selected from the group consisting of H, F, CL, CH3, CF3; R 13 is selected from the group consisting of H, F, Cl, CF3 and CH3; R 14 is H or F; R 15 is selected from the group consisting of H and CH3.

[0015] Suitably, compounds and uses according to the present invention and / or any embodiment thereof R 1 is H; R 2 is selected from the group consisting of H, F and Cl; R 3 is selected from the group consisting of H, Cl, F and Br; R 4 are H, F, Cl; R 5 is selected from the group consisting of HF and Cl; R 6is selected from the group consisting of H, F, Cl and CH3; R 7 is selected from the group consisting of HF and Cl; R 8 is selected from the group consisting of H, F, Cl and CH3; R 9 is selected from the group consisting of HF and Cl; R 11 is H; R 12 is selected from the group consisting of H, F and Cl; R 13 is selected from the group consisting of H, F and Cl; R 14 is H; R 15 is selected from the group consisting of H and CH3.

[0016] Surprisingly, the compounds described in this application are useful as medicines, in particular for the treatment of animal parasites. It has been shown that the drug can be used as a veterinary antiparasitic drug to treat or prevent infestations by was discovered.

[0017] The present invention is directed to a pharmaceutical, particularly a veterinary pharmaceutical, more preferably a veterinary antiparasitic agent. of the invention and / or its embodiments described in this application for use as a protozoan. It is understood to include compounds.

[0018] The present invention further relates to the manufacture of a medicament for treating or controlling parasitic infestations in animals. This also includes the use of the compounds of the invention and / or embodiments thereof described in this application in It is understood that:

[0019] The present invention further relates to a method for the manufacture of a medicament for protecting an animal from infestation by a parasite, It is understood that the present invention also encompasses the use of compounds of the present invention and / or embodiments thereof as described in this application. will be done.

[0020] The compounds of the present invention and / or embodiments thereof are suitably used to treat or inhibit ectoparasitic infestations. is used in control methods.

[0021] Suitably, the compounds of the present invention and / or embodiments thereof may be used in treating parasitic infestations caused by ticks. The compound is suitably used in a method in which the compound is a medaka infestation or a flea infestation. It is used against invasion by .

[0022] The compounds of the present invention and / or its embodiments are suitably used against parasites, and the parasite is a single-host tick or a multi-host tick. Suitably, the compound of the invention is used against the bull tick (Rhipicephalus microplus). can be.

[0023] In a suitable use or method of the present invention and / or any embodiment thereof, the animal is a warm-blooded animal. Suitably, the compound is administered to livestock animals, such as ruminants, cattle, etc. Furthermore, the compounds are also active against sea lice of fish. Furthermore, the compounds have been shown to be effective against infestations in companion animals, e.g. It has also been found to be active in canines or felines (especially dogs or cats). It was served.

[0024] In a suitable use or method of the present invention and / or any embodiment thereof, the animal is infested with parasites. Preferably, an existing parasitic infestation of the animal is treated or controlled. do.

[0025] In a suitable use or method of the present invention and / or any embodiment thereof, the method comprises: The animals were given once a week, once every two weeks, once a month, once every six weeks, once every two months or involves administering it once every three months.

[0026] The present invention further provides an effective amount of any of the compounds defined in any of the embodiments described herein. The compound of formula (I)-(XCII) is a compound of formula (I)-(XCII) and an inert carrier or formulation auxiliary. The present invention also relates to veterinary compositions containing the compounds described herein. The compounds are suitable for use in the treatment and control of parasitic infestations in animals (animals).

[0027] Suitably, the veterinary composition is a topical composition, an oral composition or an injectable composition. . [Brief explanation of the drawings]

[0028] [Figure 1] FIG. 1 shows the plasma concentrations of compound 453 in an oily solution (composition A) and a volatile solution (composition B). [Figure 2] FIG. 2 shows a comparison of the concentration of compound 453 in bovine blood using no CPE (composition C) and three different CPEs (compositions D, E, and F), showing that no significant improvement was observed with the inclusion of any of the CPEs. [Figure 3] FIG. 3 shows the duration of efficacy against R. microplus of greater than 90% and the onset of efficacy against R. microplus of greater than 90% for Composition G, Composition H, and the composition of Example 1. [Figure 4] FIG. 4 shows the structures of Compound 1-Compound 480. DETAILED DESCRIPTION OF THE INVENTION

[0029] Many forms of the invention may be best suited to the requirements of a particular application and are therefore preferred. This detailed description of the embodiments will enable others skilled in the art to adapt or apply the invention in its many forms. and to make applicant's invention, its principles, and its practical applications known to others skilled in the art so that they may This detailed description and its specific examples are intended to be illustrative only and are not to be construed as limiting the present invention. Although a preferred embodiment is shown, it is for illustrative purposes only.

[0030] This invention, therefore, is not limited to the preferred embodiments described herein. It is not a fixed format and can be modified in many ways. Although only some combinations of the embodiments are explicitly described in the It is to be understood that other combinations are also contemplated.

[0031] Briefly, the present invention provides a compound that can be used generally as an active ingredient in veterinary medicine. The compounds of the present invention and / or its embodiments suitably relate to compounds capable of inhibiting ectoparasites. In a method for treating or preventing an infestation by and / or from a parasitic infestation. For use in methods for protecting animals.

[0032] Surprisingly, compounds of the invention and / or embodiments thereof described herein and other similar compounds known in the art when administered to an animal in need thereof. Superior broad spectrum efficacy against harmful parasites faster and for longer periods compared to These compounds have therefore been found to exhibit a wide range of activity in accordance with the present invention and / or its implementation. Useful in the methods or uses of the embodiments.

[0033] In the following text, compounds for use according to the invention and / or embodiments thereof are , either as compounds themselves or as compounds for use in the methods according to the invention When disclosed, the term "compound of the invention" or "compound" or "the invention and / or embodiments thereof" is used. "Compounds of the form (including compounds represented by formula (I))" or "Compounds represented by formula (I) " is written as ".

[0034] It is effective against a wide range of animal parasites and various target species, as well as against animal ectoparasites. Since there are few pesticides that can be effectively used against The unexpectedly broad parasiticidal properties of these compounds for use in accordance with the embodiments are quite It's important.

[0035] The present invention and / or embodiments thereof encompassing compounds of formula (I)-(XCII) The compounds of the present invention can be used in various ways to administer them as drugs to animals. Many of these compounds exhibit desirable bioavailability and pharmacokinetics in the host animal of interest. and / or provide a desirable safety profile for their owners. A single dose of such compounds is generally effective against difficult-to-treat parasitic infestations using the relevant route of administration. It provides potent activity against a wide range of ectoparasites, including gallbladder and gallstones, while at the same time providing rapid action. They also tend to provide rapid onset and / or long duration of activity and / or a desirable safety profile. Therefore, these compounds are useful as pharmaceuticals, especially in veterinary medicine. It has been shown to be useful as an antiparasitic agent.

[0036] The compounds of the present invention and / or its embodiments exhibit desirable beneficial properties, whereby Their use in veterinary medicine is appropriate and, furthermore, the use of such compounds Resistance-breaking properties have also been shown to be highly desirable.

[0037] The Examples include compounds of the present invention and / or embodiments thereof, including compounds of formula (I). The substance is capable of controlling many veterinarily relevant parasites that affect animals, e.g. Mono- and multi-host ticks, fleas, and other parasites belonging to various classes of organisms Broad spectrum activity against bedbugs and sea lice, both in vitro and in vivo In the examples, the present invention further shows that various animals (cattle, dogs, fish, moles) The existing parasitic infestation by such parasites in the animal (Mott) is It has been shown that it is possible to treat it successfully.

[0038] Furthermore, the Examples show that the compounds of the present invention and / or embodiments thereof can be administered using various routes of administration. Effective against a wide range of animal parasites (especially ectoparasites) when administered to a variety of target animals This shows that it acts as a

[0039] Therefore, convenient and safe administration of the cyclopropylamide compounds is essential to achieve the desired effect. The compounds of the present invention and / or embodiments thereof described in this application are sufficient for By using the method, the disadvantages of the prior art can be avoided.

[0040] In a first aspect, the present invention provides a compound of formula (I) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; and, wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0041] The ring formed by C-A1-A2-A3-A4-A5 has at least one halogen atom. When substituted, these compounds have been shown to be active against animal ectoparasites. This means that the ring formed by C-A1-A2-A3-A4-A5 is This is in contrast to compounds that are not substituted with halogens.

[0042] The following comparative examples are based on the prior art documents WO2016 / 168059 and WO2 018 / 071327 indicates that it has been tested against a range of pesticide-associated parasites. WO2016 / 168059 and WO2016 / 168059 showed activity in plant protection assays. Many of the compounds in 18 / 071327 inhibited animal parasitism in the assay described in Example 1. The ring formed by A1-A5 does not have halogen substitution. Some compounds are active against pesticide parasites but not against animal parasites. It was found that the ring formed by A1-A5 is substituted with at least one halogen. The compounds shown are active against animal parasites.

[0043] In a first aspect, the compounds according to the invention are further defined as follows: R 1 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of: silyl-S(O)2NH2; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 11 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0044] In one embodiment of the present invention and / or its embodiments, R 1 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, (C (2-C6)alkenyl, (C3-C6)cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C3-C6)halocycloalkenyl (C2-C6)haloalkenyl, (C3-C6)halocycloalkenyl, (C1 -C6) haloalkoxy.

[0045] In one embodiment of the present invention and / or its embodiments, R 1 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, (C 2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1 -C6) haloalkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkene and (C1-C6)haloalkoxy, selected from the group consisting of H, F, Cl, Br, I , CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, ( C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C (1-C6)haloalkyl, (C1-C6)haloalkoxy.

[0046] In one embodiment of the present invention and / or its embodiments, R 1 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, (C 2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1 -C6) haloalkyl; H, F, Cl, Br, I, CN, NH , NO2, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloa and selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (C 1-C6) alkyl, (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C 1-C6) haloalkyl; H, F, Cl, Br, I, CN, NH 2, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl will be done.

[0047] In one embodiment of the present invention and / or its embodiments, R 1 is H.

[0048] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, ((C2-C6) alkenyl, (C2 -C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2 -C6)haloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, (C1-C6) Alkyl-S(O)2NH2, (C1-C6)haloalkyl-S(O)2NH2 and S- (halo)5.

[0049] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl , (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkane is selected from the group consisting of nyl, (C1-C6)haloalkoxy and S-(halo)5.

[0050] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkoxy is selected from the group consisting of haloalkoxy, (C1-C6)haloalkoxy and S-(halo)5.

[0051] In one embodiment of the present invention and / or its embodiments, R 2are H, F, Cl, Br, and CN , (C1-C6) alkyl, (C1-C6) haloalkyl, and S-(halo)5. is selected from.

[0052] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, and CN , CH3, CHF2, CF3, OCHF2 and S-(halo)5 .

[0053] In one embodiment of the present invention and / or its embodiments, R 2 is a group consisting of H, F, and Cl. are selected.

[0054] In one embodiment of the present invention and / or its embodiments, R 2 is selected from the group consisting of F and Cl be selected.

[0055] In one embodiment of the present invention and / or its embodiments, R 2 is Cl.

[0056] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2- C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2- C6) haloalkenyl and (C1-C6) haloalkoxy.

[0057] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl , (C1-C6)alkoxy, (C1-C6)haloalkyl and (C2-C6)haloal is selected from the group consisting of phenyl, phenyl, phenyl, phenyl;

[0058] In one embodiment of the present invention and / or its embodiments, R 2 are H, F, Cl, Br, (C is selected from the group consisting of (C1-C6) alkyl and (C1-C6) haloalkyl.

[0059] In one embodiment of the present invention and / or its embodiments, R 2 is made up of H, F, Cl and Br is selected from the group consisting of:

[0060] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, ((C2-C6) alkenyl, (C2 -C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2 -C6)haloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, (C1-C6) Alkyl-S(O)2NH2, (C1-C6)haloalkyl-S(O)2NH2 and S- (halo)5.

[0061] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C (1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkenyl and and (C1-C6)haloalkoxy.

[0062] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, CH3, CF3, CHF2, OCF3, OCH3, CH=CHF, C≡C, CH=CH2 is selected from the group consisting of:

[0063] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br and I is selected from the group consisting of:

[0064] In one embodiment of the present invention and / or its embodiments, R 3 consists of H, F, Cl, and Br The compound is selected from the group consisting of:

[0065] In one embodiment of the present invention and / or its embodiments, R 3 is the group consisting of H, F and Cl is selected from.

[0066] In one embodiment of the present invention and / or its embodiments, R 3 is H or F.

[0067] In one embodiment of the present invention and / or its embodiments, R 3 is H.

[0068] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C (1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkenyl and and (C1-C6)haloalkoxy.

[0069] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, and (C1-C6)haloalkoxy.

[0070] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br, I, Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy do.

[0071] In one embodiment of the present invention and / or its embodiments, R 3 are H, F, Cl, Br and I is selected from the group consisting of:

[0072] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, ((C2-C6) alkenyl, (C2 -C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2 -C6)haloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, (C1-C6) Alkyl-S(O)2NH2, (C1-C6)haloalkyl-S(O)2NH2 and S- (halo)5.

[0073] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl , (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkane is selected from the group consisting of nyl, (C1-C6)haloalkoxy and S-(halo)5.

[0074] In one embodiment of the present invention and / or its embodiments, R4 are H, F, Cl, Br, (C 1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2 -C6)alkynyl(C1-C6)alkoxy, (C2-C6)haloalkenyl and S- (halo)5.

[0075] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, and CH 3, from the group consisting of CF3, OCH3, CH=CHF, C≡C, CH=CH2 and SF5 be selected.

[0076] In one embodiment of the present invention and / or its embodiments, R 4 is made up of H, F, Cl and Br is selected from the group consisting of:

[0077] In one embodiment of the present invention and / or its embodiments, R 4 is the group consisting of H, F and Cl is selected from.

[0078] In one embodiment of the present invention and / or its embodiments, R 4 is Cl.

[0079] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2- C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2- C6) haloalkenyl, (C1-C6) haloalkoxy.

[0080] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl , (C1-C6)alkoxy, (C1-C6)haloalkyl and (C2-C6)haloal is selected from the group consisting of phenyl, phenyl, phenyl, phenyl;

[0081] In one embodiment of the present invention and / or its embodiments, R 4 are H, F, Cl, Br, (C is selected from the group consisting of (C1-C6) alkyl and (C1-C6) haloalkyl.

[0082] In one embodiment of the present invention and / or its embodiments, R 4 consists of H, F, Cl, and Br The compound is selected from the group consisting of:

[0083] In one embodiment of the present invention and / or its embodiments, R 5 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) alkyl -S(O)2NH2, (C1-C6)haloalkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2- C6) alkynyl, (C2-C6) haloalkenyl, (C3-C6) cycloalkyl, ( C3-C6)halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH (C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alkyl CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl) (=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , N.H. (C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl NH(C1-C6) alkylphenyl, NH(S(O)2(C1-C6) alkyl) , NH—C(═O)O(C1-C6) alkyl, oxazolyl, phenyl, pyrazolyl, It is selected from the group consisting of pyridinyl, thiazolyl, thienyl and triazolyl.

[0084] In one embodiment of the present invention and / or its embodiments, R 5 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) haloa Alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) a alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkyl, (C3-C 6) Halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH(C1- C6) alkyl, C(=O)O(C1-C6) alkyl, N((C1-C6) alkyl) 2. NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , NH(C 1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl, is selected from the group consisting of NH—C(═O)O(C1-C6)alkyl.

[0085] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0086] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkyl is selected from the group consisting of:

[0087] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3 and CF3.

[0088] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br and I is selected from the group consisting of:

[0089] In one embodiment of the present invention and / or its embodiments, R 5 is the group consisting of H, F and Cl is selected from.

[0090] In one embodiment of the present invention and / or its embodiments, R 5 is H or F.

[0091] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10, N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0092] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 and N(C1-C6) Alkyl-C(=O)lR 10 is selected from the group consisting of:

[0093] In one embodiment of the present invention and / or its embodiments, R 5 are H, F, Cl, CN, NO 2. NH(C1-C6) alkyl and (C1-C6) alkyl .

[0094] In one embodiment of the present invention and / or its embodiments, R 5 is H, F, Cl, CN and ( C1-C6) alkyl.

[0095] In one embodiment of the present invention and / or its embodiments, R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) alkyl -S(O)2NH2, (C1-C6)haloalkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2- C6) alkynyl, (C2-C6) haloalkenyl, (C3-C6) cycloalkyl, ( C3-C6)halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH (C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alkyl CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl) (=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , N.H. (C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl NH(C1-C6) alkylphenyl, NH(S(O)2(C1-C6) alkyl) , NH—C(═O)O(C1-C6) alkyl, oxazolyl, phenyl, pyrazolyl, It is selected from the group consisting of pyridinyl, thiazolyl, thienyl and triazolyl.

[0096] In one embodiment of the present invention and / or its embodiments, R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) haloa Alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) a alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkyl, (C3-C 6) Halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH(C1- C6) alkyl, C(=O)O(C1-C6) alkyl, N((C1-C6) alkyl) 2. NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , NH(C 1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl, is selected from the group consisting of NH—C(═O)O(C1-C6)alkyl.

[0097] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0098] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, ( is selected from the group consisting of (C2-C6)alkenyl and (C2-C6)haloalkenyl.

[0099] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0100] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0101] In one embodiment of the present invention and / or its embodiments, R6 are H, F, Cl, Br and C H3.

[0102] In one embodiment of the present invention and / or its embodiments, R 6 is H, F, Cl and CH3 is selected from the group consisting of:

[0103] In one embodiment of the present invention and / or its embodiments, R 6 is H or F.

[0104] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0105] In one embodiment of the present invention and / or its embodiments, R 6 are H, F, Cl, NH(C1 -C6) alkyl, (C1-C6) alkyl, NHC(=O)R 10 and N(C1-C6 )Alkyl-C(=O)lR 10 is selected from the group consisting of:

[0106] In one embodiment of the present invention and / or its embodiments, R 6 is H, F, NH(C1-C6 ) alkyl, NHC(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 is selected from the group consisting of:

[0107] In one embodiment of the present invention and / or its embodiments, R 6 is H, F and NH(C1-C 6) alkyl.

[0108] In one embodiment of the present invention and / or its embodiments, R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) alkyl -S(O)2NH2, (C1-C6)haloalkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2- C6) alkynyl, (C2-C6) haloalkenyl, (C3-C6) cycloalkyl, ( C3-C6)halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH (C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alkyl CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl) (=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , N.H. (C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl NH(C1-C6) alkylphenyl, NH(S(O)2(C1-C6) alkyl) , NH—C(═O)O(C1-C6) alkyl, oxazolyl, phenyl, pyrazolyl, It is selected from the group consisting of pyridinyl, thiazolyl, thienyl and triazolyl.

[0109] In one embodiment of the present invention and / or its embodiments, R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) haloa Alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) a alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkyl, (C3-C 6) Halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH(C1- C6) alkyl, C(=O)O(C1-C6) alkyl, N((C1-C6) alkyl) 2. NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , NH(C 1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl, is selected from the group consisting of NH—C(═O)O(C1-C6)alkyl.

[0110] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0111] In one embodiment of the present invention and / or its embodiments, R 7are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, ( is selected from the group consisting of (C2-C6)alkenyl and (C2-C6)haloalkenyl.

[0112] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0113] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0114] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, Br and I is selected from the group consisting of:

[0115] In one embodiment of the present invention and / or its embodiments, R 7 is the group consisting of H, F and Cl is selected from.

[0116] In one embodiment of the present invention and / or its embodiments, R 7 is H or F.

[0117] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0118] In one embodiment of the present invention and / or its embodiments, R 7 are H, F, Cl, NH(C1 -C6) alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1 -C6)alkoxy and (C1-C6)haloalkyl.

[0119] In one embodiment of the present invention and / or its embodiments, R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) alkyl -S(O)2NH2, (C1-C6)haloalkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2- C6) alkynyl, (C2-C6) haloalkenyl, (C3-C6) cycloalkyl, ( C3-C6)halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH (C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alkyl CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl) (=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , N.H. (C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl NH(C1-C6) alkylphenyl, NH(S(O)2(C1-C6) alkyl) , NH—C(═O)O(C1-C6) alkyl, oxazolyl, phenyl, pyrazolyl, It is selected from the group consisting of pyridinyl, thiazolyl, thienyl and triazolyl.

[0120] In one embodiment of the present invention and / or its embodiments, R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) haloa Alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) a alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkyl, (C3-C 6) Halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH(C1- C6) alkyl, C(=O)O(C1-C6) alkyl, N((C1-C6) alkyl) 2. NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , NH(C 1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl, is selected from the group consisting of NH—C(═O)O(C1-C6)alkyl.

[0121] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, C1-C6) haloalkoxy Le, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(=O )(C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0122] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, ( is selected from the group consisting of (C2-C6)alkenyl and (C2-C6)haloalkenyl.

[0123] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0124] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0125] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br and C H3.

[0126] In one embodiment of the present invention and / or its embodiments, R 8 is H, F, Cl and CH3 is selected from the group consisting of:

[0127] In one embodiment of the present invention and / or its embodiments, R 8 is H or F.

[0128] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) alkyl, N((C1-C6) alkyl (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloal Kill, NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , C(= O) (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) haloalkenyl and C(=O)-O-(C1-C6) alkyl.

[0129] In one embodiment of the present invention and / or its embodiments, R 8 are H, F, Cl, NH(C1 -C6) alkyl and (C1-C6) alkyl.

[0130] In one embodiment of the present invention and / or its embodiments, R 8 is H, F and NH(C1-C 6) alkyl.

[0131] In one embodiment of the present invention and / or its embodiments, R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) alkyl -S(O)2NH2, (C1-C6)haloalkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2- C6) alkynyl, (C2-C6) haloalkenyl, (C3-C6) cycloalkyl, ( C3-C6)halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH (C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alkyl CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl) (=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , N.H. (C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl NH(C1-C6) alkylphenyl, NH(S(O)2(C1-C6) alkyl) , NH—C(═O)O(C1-C6) alkyl, oxazolyl, phenyl, pyrazolyl, It is selected from the group consisting of pyridinyl, thiazolyl, thienyl and triazolyl.

[0132] In one embodiment of the present invention and / or its embodiments, R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =O, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkylphenyl, (C1-C6) haloa Alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) a alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkyl, (C3-C 6) Halocycloalkyl, C(=O)(C1-C6)alkyl, C(=O)NH(C1- C6) alkyl, C(=O)O(C1-C6) alkyl, N((C1-C6) alkyl) 2. NHC(=O)R 10 , N(C1-C6) alkyl-C(=O)lR 10 , NH(C 1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6) alkynyl, is selected from the group consisting of NH—C(═O)O(C1-C6)alkyl.

[0133] R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, C1-C6 haloalkyl, NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkene from alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl 10. The compound and use according to any of the preceding claims, selected from the group consisting of:

[0134] In one embodiment of the present invention and / or its embodiments, R 9 are H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, ( is selected from the group consisting of (C2-C6)alkenyl and (C2-C6)haloalkenyl.

[0135] In one embodiment of the present invention and / or its embodiments, R 9 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0136] In one embodiment of the present invention and / or its embodiments, R 9 are H, F, Cl, Br, I, Selected from the group consisting of CH3, OCH3, CH=CHF, CH=CH and CF3.

[0137] In one embodiment of the present invention and / or its embodiments, R 9 are H, F, Cl, Br and I is selected from the group consisting of:

[0138] In one embodiment of the present invention and / or its embodiments, R 9 is the group consisting of H, F and Cl is selected from.

[0139] In one embodiment of the present invention and / or its embodiments, R9 is H or F.

[0140] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 is that they are combined together with the atoms forming the ring, the ring containing 5 or 6 atoms, The atoms consist of -CH2-, -CH=, =CH-, -N=, =N-, -NH- and -O- The compound is selected from the group consisting of:

[0141] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 is that they are combined together with the atoms forming the ring, the ring containing 5 or 6 atoms, The atom is selected from the group consisting of -CH2-, -CH=, =CH-, -N=, =N- and -NH-. be selected.

[0142] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 The ring formed by , (C1-C3) alkyl, F, Cl, Br, I, CN may be substituted with a substituent of the formula:

[0143] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 The ring formed by , substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F and Cl It may be done.

[0144] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 The ring formed by , CH3, F, and Cl. .

[0145] In one embodiment of the present invention and / or its embodiments, R 6 and R 7 The ring formed by , not replaced.

[0146] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 is that they are combined together with the atoms forming the ring, the ring containing 5 or 6 atoms, The atoms consist of -CH2-, -CH=, =CH-, -N=, =N-, -NH- and -O- The compound is selected from the group consisting of:

[0147] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 is that they are combined together with the atoms forming the ring, the ring containing 5 or 6 atoms, The atom is selected from the group consisting of -CH2-, -CH=, =CH-, -N=, =N- and -NH-. be selected.

[0148] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 The ring formed by , (C1-C3) alkyl, F, Cl, Br, I, and CN. It may be substituted with the above substituents.

[0149] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 The ring formed by , substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F and Cl It may be done.

[0150] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 The ring formed by , CH3, F, and Cl. .

[0151] In one embodiment of the present invention and / or its embodiments, R 7 and R 8 The ring formed by , not replaced.

[0152] In one embodiment of the present invention and / or its embodiments, R 10 H, (C1-C6) Al alkyl, (C1-C6) alkyloxy-(C1-C6)-alkyl, (C2-C6) alkyl (C2-C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) a Alkyloxy-(C1-C6)haloalkyl, (C1-C6)alkyl-(C3-C6) Cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothio Selected from the group consisting of phenyl, thianyl, phenyl and (C1-C6) alkylphenyl It is selected.

[0153] In one embodiment of the present invention and / or its embodiments, R 10 is (C1-C6) alkyl , (C1-C6) alkyloxy-(C1-C6) alkyl, (C2-C6) alkenyl , (C2-C6)alkynyl, (C1-C6)haloalkyl, (C1-C6)alkyloxy Oxy-(C1-C6)haloalkyl, (C1-C6)alkyl-(C3-C6)cycloalkyl The alkyl group is selected from the group consisting of alkyl, tetrahydrofuranyl and phenyl.

[0154] In one embodiment of the present invention and / or its embodiments, R 11are H, F, Cl, Br, and I , CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, ( C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C (1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalkoxy and (C1-C6)alkyl-S(O)2NH2.

[0155] In one embodiment of the present invention and / or its embodiments, R 11 are H, F, Cl, Br, and I , CN, NH2, NO2 and (C1-C6) alkyl.

[0156] In one embodiment of the present invention and / or its embodiments, R 11 are H, F, Cl, Br, and I and CH3.

[0157] In one embodiment of the present invention and / or its embodiments, R 11 are H, F, Cl and CH3 is selected from the group consisting of:

[0158] In one embodiment of the present invention and / or its embodiments, R 11 is H.

[0159] In one embodiment of the present invention and / or its embodiments, R 12 are H, F, Cl, Br, and I , CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, ( C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1 -C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalkoxy and (C1-C6) alkyl-S(O)2NH2.

[0160] In one embodiment of the present invention and / or its embodiments, R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl; (C (1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkenyl and and (C1-C6)haloalkoxy.

[0161] In one embodiment of the present invention and / or its embodiments, R 12 are H, F, Cl, Br, and I , (C1-C6) alkyl, (C1-C6) haloalkyl.

[0162] In one embodiment of the present invention and / or its embodiments, R 12 are H, F, Cl, CH3 and and CF3.

[0163] In one embodiment of the present invention and / or its embodiments, R 12 is H or F.

[0164] In one embodiment of the present invention and / or its embodiments, R 12 is H.

[0165] In one embodiment of the present invention and / or its embodiments, R 13 are H, F, Cl, Br, and I , CN, NH2, NO2, CHO, (C1-C6) alkyl, (C3-C6) cycloalkenyl Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) halo From the group consisting of alkoxy, (C1-C6) alkyl-S(O)2NH2 and triazolyl are selected.

[0166] In one embodiment of the present invention and / or its embodiments, R 13 are H, F, Cl, Br, and I , CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C1 —C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkenyl, and (C1-C6)haloalkoxy.

[0167] In one embodiment of the present invention and / or its embodiments, R 13 are H, F, Cl, Br, and I , (C1-C6) alkyl, and (C1-C6) haloalkyl.

[0168] In one embodiment of the present invention and / or its embodiments, R 13 are H, F, Cl, Br, and I , (C1-C6) alkyl, (C1-C6) haloalkyl.

[0169] In one embodiment of the present invention and / or its embodiments, R 13 are H, F, Cl, CH3 and and CF3.

[0170] In one embodiment of the present invention and / or its embodiments, R 13 is Cl or F.

[0171] In one embodiment of the present invention and / or its embodiments, R 13 is Cl.

[0172] In one embodiment of the present invention and / or its embodiments, R 14 are H, F, Cl, Br, and I , CN, NH2, NO2, (C1-C6) alkyl, (C3-C6) cycloalkyl, ( C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C (1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalkoxy and (C1-C6)alkyl-S(O)2NH2.

[0173] In one embodiment of the present invention and / or its embodiments, R 14 are H, F, Cl, Br, and I , CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C1 —C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)haloalkenyl, and (C1-C6)haloalkoxy.

[0174] In one embodiment of the present invention and / or its embodiments, R 14 are H, F, Cl, Br, and I , (C1-C6) alkyl, and (C1-C6) haloalkyl.

[0175] In one embodiment of the present invention and / or its embodiments, R 14 are H, F, Cl, CH3 and and CF3.

[0176] In one embodiment of the present invention and / or its embodiments, R 14 is selected from the group consisting of H and F be selected.

[0177] In one embodiment of the present invention and / or its embodiments, R 14 is H.

[0178] In one embodiment of the present invention and / or its embodiments, R 15 H, (C1-C6) Al alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl and (C1-C6) halo is selected from the group consisting of alkyl.

[0179] In one embodiment of the present invention and / or its embodiments, R 15 H, (C1-C6) Al and (C1-C6)haloalkyl.

[0180] In one embodiment of the present invention and / or its embodiments, R 15 H, CH3 and CF3 is selected from the group consisting of:

[0181] In one embodiment of the present invention and / or its embodiments, R 15 is a group consisting of H and CH3 is selected from.

[0182] In one embodiment of the present invention and / or its embodiments, R 15 is H.

[0183] In one embodiment of the present invention and / or its embodiments, R 1 is selected from the group consisting of HF and Cl; R 2 is selected from the group consisting of H, F and Cl; R 3 is selected from the group consisting of H, F and Cl; R 4 is selected from the group consisting of H, F and Cl; R 5 is selected from the group consisting of HF, Cl, Br, and I; R 6 is selected from the group consisting of H, F and Cl, Br and CH3; R 7 is selected from the group consisting of HF, Cl, Br, and I; R 8 is selected from the group consisting of H, F, Cl, Br and CH3; R 9 is selected from the group consisting of HF, Cl, Br, and I; R 11 is H; R 12is selected from the group consisting of H, F, CL, CH3, CF3; R 13 is selected from the group consisting of H, F, Cl, CF3 and CH3; R 14 is H or F; and R 15 is selected from the group consisting of H and CH3.

[0184] In one embodiment of the present invention and / or its embodiments, R 1 is H; R 2 is selected from the group consisting of H, F and Cl; R 3 is selected from the group consisting of H, Cl, F and Br; R 4 are H, F, Cl; R 5 is selected from the group consisting of HF and Cl; R 6 is selected from the group consisting of H, F, Cl and CH3; R 7 is selected from the group consisting of HF and Cl; R 8 is selected from the group consisting of H, F, Cl and CH3; R 9 is selected from the group consisting of HF and Cl; R 11 is H; R 12 is selected from the group consisting of H, F and Cl; R 13 is selected from the group consisting of H, F and Cl; R 14 is H; R 15 is selected from the group consisting of H and CH3.

[0185] In one embodiment of the present invention and / or its embodiments, R 1 is H; R 2is selected from the group consisting of H, F and Cl; R 3 is selected from the group consisting of H, Cl, F and Br; R 4 are H, F, Cl; R 5 is selected from the group consisting of HF and Cl; R 6 is selected from the group consisting of H, F and CH3; R 7 is selected from the group consisting of HF and Cl; R 8 is selected from the group consisting of H, F and CH3; R 9 is selected from the group consisting of HF and Cl; R 11 is H; R 12 is selected from the group consisting of H and F; R 13 is selected from the group consisting of F and Cl; R 14 is H; R 15 is selected from the group consisting of H and CH3.

[0186] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 , R 8 , R 9 brain At least one of them is a substituent selected from the group consisting of F, Cl and Br.

[0187] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 , R 8 , R 9 brain At least one of them is a substituent selected from the group consisting of F and Cl.

[0188] In one embodiment of the present invention and / or its embodiments, R5 , R 6 , R 7 , R 8 , R 9 brain At least one of them is F.

[0189] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 , R 8 , R 9 brain At least two of them are substituents selected from the group consisting of F, Cl and Br.

[0190] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 , R 8 , R 9 brain At least two of them are substituents selected from the group consisting of F and Cl.

[0191] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 , R 8 , R 9 brain At least two of them are F.

[0192] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 At least one of and 1 is a substituent selected from the group consisting of F, Cl and Br.

[0193] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 At least one of and 1 is a substituent selected from the group consisting of F and Cl.

[0194] In one embodiment of the present invention and / or its embodiments, R 5 , R 6 , R 7 At least one of Also, 1 is F.

[0195] In one embodiment of the present invention and / or its embodiments, R 5 , R 7 At least one of , F, Cl and Br.

[0196] In one embodiment of the present invention and / or its embodiments, R 5 , R 7 At least one of , F and Cl.

[0197] In one embodiment of the present invention and / or its embodiments, R 5 , R 7 At least one of , F.

[0198] In one embodiment of the present invention and / or its embodiments, R 5 and R 7 are F and C, respectively. is a substituent selected from the group consisting of l and Br.

[0199] In one embodiment of the present invention and / or its embodiments, R 5 and R 7 are F and is a substituent selected from the group consisting of Cl.

[0200] In one embodiment of the present invention and / or its embodiments, R 5 and R 7 are F, respectively. do.

[0201] In one embodiment of the present invention and / or its embodiments, A1, A2, A3, A4, A5 Of these, 0, 1 or 2 is N.

[0202] In one embodiment of the present invention and / or its embodiments, the compound is a prodrug, At least one of A1, A2, A3, A4, and A5 is N=O.

[0203] In one embodiment of the present invention and / or its embodiments, A1, A2, A3, A4, A5 Of these, 0, 1 or 2 is N=O.

[0204] In one embodiment of the present invention and / or its embodiments, A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; Here, three or less of A1, A2, A3, A4, and A5 are N.

[0205] In one embodiment of the present invention and / or its embodiments, A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; Here, 0 or 1 of A1, A2, A3, A4, and A5 is N.

[0206] In one embodiment of the present invention and / or its embodiments, A1 is CR 5 or N; A2 is CR 6 Or N A3 is CR7 and; A4 is CR 8 and; A5 is CR 9 and; Here, 0 or 1 in A1 or A2 is N.

[0207] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 5 , R 6 , R 7 , R 8 , R 9 At least one of the groups consists of F, Cl, Br and I. and wherein R is a substituent selected from the group 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 14 , R 15 , A1, A2, A3, A4 and A5 are Defined as defined elsewhere herein.

[0208] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0209] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0210] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein no more than three of A1, A2, A3, A4, and A5 are N; R5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0211] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A2, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7 is selected from the group consisting of H, F and Cl; Or, R 6 and R 7contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0212] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (II) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 of A1 or A2 is N; R 5 is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 6 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0213] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 13 , R 14 , R 15 , A1, A2, A3, A4 and A5 are defined as defined elsewhere herein, and where R 5 , R 6 , R 7 , R 8 , R 9At least one of F, Cl, Br and and I.

[0214] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10, NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0215] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0216] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein no more than three of A1, A2, A3, A4, and A5 are N; R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0217] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A2, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7is selected from the group consisting of H, F and Cl; Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 13is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0218] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (III) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 of A1 or A2 is N; R 5 is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 6is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 13 is Cl; R 14 is H; R 15 is H; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0219] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and its N-oxide, veterinarily acceptable acid addition salt, salt derivative Conductors, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 14 , A1, A2, A3, A4 and A5 are defined as defined elsewhere herein, and where R 5 , R 6 , R 7 , R 8 , R9 At least one of F, Cl, Br and and I.

[0220] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10, NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0221] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14is selected from the group consisting of H, F, Cl, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0222] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein no more than three of A1, A2, A3, A4, and A5 are N; R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0223] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A2, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7 is selected from the group consisting of H, F and Cl; Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0224] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IV) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 of A1 or A2 is N; R 5is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 6 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 12 is H; R 13 is Cl; R 14 is H; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0225] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 15 , A1, A2, A3, A4 and A5 are defined as defined elsewhere herein, and where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and and I.

[0226] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6)haloalkyl; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0227] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl and Br and I is a substituent selected from the group consisting of:

[0228] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein no more than three of A1, A2, A3, A4, and A5 are N; R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0229] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A2, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7 is selected from the group consisting of H, F and Cl; Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3; where R 5 , R 6 , R 7 , R 8 , R 9 at least one of which is a group consisting of F and Cl is a substituent selected from:

[0230] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (V) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 of A1 or A2 is N; R 5 is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 6 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H; where R 5 , R 6 , R 7 , R 8 , R 9 at least one of which is a group consisting of F and Cl is a substituent selected from:

[0231] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R9 , R 13 , A1, A2, A3, A4 and A5 are defined as defined elsewhere herein, and where R 5 , R 6 , R 7 , R 8 , R 9 At least one of the groups is selected from the group consisting of F, Cl, Br and I. is a substituent selected from the group consisting of:

[0232] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10, N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; where R5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0233] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR5 , where N=O or N; A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than three of A1, A2, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9At least one of F, Cl and Br and I is a substituent selected from the group consisting of:

[0234] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein no more than three of A1, A2, A3, A4, and A5 are N; R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; where R 5 , R 6 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0235] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A2, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7 is selected from the group consisting of H, F and Cl; Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 13 is Cl or F; where R 5 , R 6 , R 7 , R 8 , R 9 at least one of which is a group consisting of F and Cl is a substituent selected from:

[0236] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 or N; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 of A1 or A2 is N; R 5 is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 6 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 13 is Cl; where R 5 , R 6, R 7 , R 8 , R 9 at least one of which is a group consisting of F and Cl is a substituent selected from:

[0237] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 12 , R 13 , R 14 , R 15 is defined elsewhere in this specification It is defined as follows.

[0238] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl.

[0239] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0240] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3, and CF3I.

[0241] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3.

[0242] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H.

[0243] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 12 , R 13 , R 14 and R 15 is defined elsewhere in this specification It is defined as follows.

[0244] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl.

[0245] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0246] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3 and CF3.

[0247] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3.

[0248] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (VIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H.

[0249] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 12 , R 13 , R 14 and R 15 is defined elsewhere in this specification It is defined as follows.

[0250] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl.

[0251] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0252] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0253] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3.

[0254] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (IX) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H.

[0255] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 14 , R 15 , A2, A3, A4 and A5 are defined as defined anywhere herein; and where R 6 , R 7 , R8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0256] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than two of A2, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 6 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10, NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 6 and R 7 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl; where R 6 , R 7 , R 8 , R 9 At least one of the groups consists of F, Cl, Br and I. The substituent is selected from the group consisting of:

[0257] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A2 is CR 6 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than two of A2, A3, A4, and A5 are N or N=O; R 6 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 6 and R 7 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. and optionally substituted with one or more substituents selected from the group consisting of aryl, ... and aryl; R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 6 , R 7 , R 8 , R 9 At least one of the following is selected from F, Cl, Br, and I: is a substituent selected from the group consisting of:

[0258] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; where no more than two of A2, A3, A4, and A5 are N; R 6 is H, F, Cl, NH(C1-C6) alkyl, (C1-C6) alkyl, NH C(=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of Selected; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 6 , R 7 , R 8 , R 9 At least one of the groups consists of F, Cl, Br and I. The substituent is selected from the group consisting of:

[0259] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A2 is CR 6 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A2, A3, A4, and A5 is N; R 6 is H, F, NH(C1-C6) alkyl, NHC(=O)R 10 and N(C1- C6)Alkyl-C(=O)lR 10 selected from the group consisting of: R 7 is selected from the group consisting of H, F and Cl; Or, R 6 and R 7 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 6 and R 7 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3; where R 6 , R 7 , R 8 , R 9 At least one of the groups is selected from the group consisting of F and Cl. is a substituent selected from the group consisting of aryl, ...

[0260] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (X) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A2 is CR 6 or N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 in A2 is N; R 6 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H; where R 6 , R 7 , R 8 , R 9 At least one of the groups is selected from the group consisting of F and Cl. is a substituent selected from the group consisting of aryl, ...

[0261] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 14 , R 15 , A1, A3, A4 and A5 are defined as defined anywhere herein; and where R 5 , R 7 , R 8 , R 9 At least one of F, Cl, Br and I is a substituent selected from the group consisting of:

[0262] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, A1 is CR 5 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than two of A1, A3, A4, and A5 are N or N=O; R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 5 are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH , NH2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6) Alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloa Alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH 2. (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkene nyl, (C3-C6)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6 ) halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl ((C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C 6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O )NH(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) Alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl)(C(=O)(C1-C6) alkyl), N((C1-C6) alkyl)(C (=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)a N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl) C(=O)O(C1-C6) alkyl), N((C1-C6) alkyl)2, N(C(= O)O(C1-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkyl C(=O)(C1-C6) alkyl), NHC(=O)R 10 , N(C1-C6)Al Kill-C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S( O)2(C1-C6)alkyl), NH-C(=O)O(C1-C6)alkyl, oxa Zolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl ), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN) ((C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6 ) haloalkyl, S(O)2(C1-C6) alkyl, S(O)2(C1-C6) haloa selected from the group consisting of alkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 7 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 8 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10, NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= From the group consisting of: ═N—, —NH—, —O—, —S(O)—, —S(O)2— and —S— is selected, where R 7 and R 8 The ring formed by is (C1-C3) alkyl, F, substituted with one or more substituents selected from the group consisting of Cl, Br, I, CN, NO2 and =O It may be; R 9 are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, N H2, =O, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl alkylphenyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) haloalco oxy, (C1-C6)haloalkyl, (C1-C6)haloalkyl-S(O)2NH2, (C2-C6) alkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl , (C3-C6) cycloalkenyl, (C3-C6) cycloalkyl, (C3-C6) halo halocycloalkenyl, (C3-C6) halocycloalkyl, (C1-C6) alkyl (( C1-C6) alkyl)(=NO(C1-C6) alkyl), C(=NO(C1-C6) alkyl)(C1-C6) alkyl, C(=O)(C1-C6) alkyl, C(=O)N H(C1-C6) alkyl, C(=O)NH phenyl, C(=O)O(C1-C6) alk alkyl, CH(=NO(C1-C6) alkyl), imidazolyl, N((C1-C6) alkyl N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl), N((C1-C6)alkyl)(C(= O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl N((C1-C6) alkyl)(C(=O)(C1-C6) haloalkyl), N((C1-C6) alkyl)(C( =O)O(C1-C6)alkyl), N((C1-C6)alkyl), N(C(=O) O(C1-C6) alkyl)2, N=CH-phenyl, NH((C1-C6) alkylC (=O)(C1-C6)alkyl), NHC(=O)R 10 , N(C1-C6) alkyl -C(=O)lR 10 , NH(C1-C6) alkyl, NH(C1-C6) alkenyl, NH(C1-C6)alkynyl, NH(C1-C6)alkylphenyl, NH(S(O) 2(C1-C6) alkyl), NH-C(=O)O(C1-C6) alkyl, oxazolidinyl phenyl, pyrazolyl, pyridinyl, S(=NCN)((C1-C6) alkyl), S(C1-C6) alkyl, S(C1-C6) haloalkyl, S(O)(=NCN)(( C1-C6) alkyl), S(O)(C1-C6) alkyl, S(O)(C1-C6) ha S(O)2(C1-C6)haloalkyl, S(O)2(C1-C6)alkyl, S(O)2(C1-C6)haloalkyl selected from the group consisting of aryl, SCN, thiazolyl, thienyl and triazolyl; Here, each of alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkyl alkenyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halo Cycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thiazole Enyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C1-C6)al alkyl, NH(C3-C6)cycloalkylCH2O(C1-C6)alkyl, NH(C3 -C6)cycloalkylCH2O(C1-C6)haloalkyl, NHCH2(C3-C6 ) cycloalkyl, NH2, NO2, oxo, (C1-C6) alkyl, (C1-C6) alkyl, (C1-C6)alkoxy and C(=O)O-(C1-C6)alkyl and optionally substituted with one or more substituents selected from the group consisting of: R 10 is H, (C1-C6) alkyl, C3-C6) cycloalkyl, (C1-C 6) Alkyloxy-(C1-C6)-alkyl, (C2-C6)alkenyl, (C2- C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkyloxy-(C 1-C6)haloalkyl, C1-C6)alkyloxy-(C2-C6)-alkenyl, (C1-C6) alkyl-(C3-C6) cycloalkyl, heterocycle, aryl and (C 1-C6) alkylphenyl; R 12 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl; where R 5 , R 7 , R 8 , R 9 At least one of the groups consists of F, Cl, Br and I. The substituent is selected from the group consisting of:

[0263] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: A1 is CR 5 , where N=O or N; A3 is CR 7 , where N=O or N; A4 is CR 8 , where N=O or N; A5 is CR 9 , where N=O or N; wherein no more than two of A1, A3, A4, and A5 are N or N=O; R 5 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 7 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 8 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, —NH—, and —O—, wherein R 7 and R 8 Shaped by The ring formed is selected from the group consisting of (C1-C3) alkyl, F, Cl, Br, I, and CN. may be substituted with one or more substituents selected from the group consisting of aryl, ... R 9 is H, F, Cl, Br, I, CN, NO2, NH2, =O, NH(C1-C6) Alkyl, N((C1-C6) alkyl)2, (C1-C6) alkyl, (C1-C6) Alkoxy, (C1-C6)haloalkyl, NHC(=O)R 10 , N(C1-C6)A Rukill-C(=O)lR 10 , C(=O)(C1-C6) alkyl, (C2-C6) alkoxy alkenyl, (C2-C6)haloalkenyl and C(=O)-O-(C1-C6)alkyl selected from the group consisting of: R 10 is H, (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C 6)-alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, ((C1-C 6) haloalkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C 1-C6) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl, piperidinyl phenyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl and (C1-C6 ) alkylphenyl; R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 7 , R 8 , R 9 At least one of the following is selected from F, Cl, Br, and I: is a substituent selected from the group consisting of:

[0264] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; A1 is CR 5 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; where no more than two of A1, A3, A4, and A5 are N; R 5 are H, F, Cl, Br, I, CN, NO2, NH(C1-C6) alkyl, (C (1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, NHC (=O)R 10 and N(C1-C6) alkyl-C(=O)lR 10 Selected from the group consisting of be; R 7 is H, F, Cl, NH(C1-C6) alkyl, N((C1-C6) alkyl) 2. (C1-C6) alkyl, (C1-C6) alkoxy and (C1-C6) haloalkoxy selected from the group consisting of: R 8 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of (C1-C3) alkyl, F, and Cl. may be substituted; R 9 is a group consisting of H, F, Cl, NH(C1-C6) alkyl and (C1-C6) alkyl selected from the group consisting of: R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3; where R 5 , R 7 , R 8 , R 9 At least one of the groups consists of F, Cl, Br and I. The substituent is selected from the group consisting of:

[0265] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: A1 is CR 5 or N; A3 is CR 7 or N; A4 is CR 8 or N; A5 is CR 9 or N; wherein 0 or 1 of A1, A3, A4, and A5 is N; R 5 is H, F, Cl, CN, NO2, NH(C1-C6) alkyl and (C1-C6 ) alkyl; R 7 is selected from the group consisting of H, F and Cl; R 8 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; Or, R 7 and R 8 contains 5 or 6 atoms together with the atoms to which they are attached forming a ring, wherein the atoms forming the ring are -CH2-, -CH=, =CH-, -N= , ═N—, and —NH—, wherein R 7 and R 8 formed by The ring may be substituted with one or more substituents selected from the group consisting of CH3, F, and Cl. often; R 9 is selected from the group consisting of H, F, and NH(C1-C6)alkyl; R 10 is (C1-C6) alkyl, (C1-C6) alkyloxy-(C1-C6) Alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) halo Alkyl, (C1-C6) alkyloxy-(C1-C6) haloalkyl, (C1-C6 ) alkyl-(C3-C6) cycloalkyl, tetrahydrofuranyl and phenyl selected from the group consisting of: R 12 is H or F; R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3; where R 5 , R 7 , R 8 , R 9 At least one of the groups is selected from the group consisting of F and Cl. is a substituent selected from the group consisting of aryl, ...

[0266] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XI) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; A1 is CR 5 is N; A3 is CR 7 and; A4 is CR 8 and; A5 is CR 9 and; wherein 0 or 1 in A1 is N; R 5 is selected from the group consisting of H, F, Cl, CN, and (C1-C6) alkyl; R 7 is selected from the group consisting of H and F; R 8 is selected from the group consisting of H and F; R 9 is selected from the group consisting of H and F; R 12 is H; R 13 is Cl; R 14 is H; R 15 is H; where R 5 , R 7 , R 8 , R 9 At least one of the groups is selected from the group consisting of F and Cl. is a substituent selected from the group consisting of aryl, ...

[0267] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 13 , R 14 , R 15 is defined elsewhere in this specification It is defined as follows.

[0268] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 3are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6) Haloalkyl, (C1-C6)alkyl-S(O)2NH2 and (C1-C6)haloal selected from the group consisting of yl-S(O)2NH2 and S-(halo)5; R 13 are H, F, Cl, Br, I, CN, NH2, NO2, CHO, (C1-C6) Alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6) Cycloalkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C 6) Haloalkyl, (C3-C6)halocycloalkyl, (C2-C6)haloalkenyl , (C3-C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C 6) alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1-C6)haloalkyl, S(O)(C1-C6)haloalkyl, S(O)2(C 1-C6) haloalkyl, (C1-C6) alkyl-S(O)2NH2, (C1-C6) selected from the group consisting of haloalkyl-S(O)NH and triazolyl; R 14 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl , (C3-C6) cycloalkyl, (C2-C6) alkenyl, (C3-C6) cycloa alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo Alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3 -C6)halocycloalkenyl, (C1-C6)haloalkoxy, S(C1-C6)alkoxy alkyl, S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1 -C6) haloalkyl, S(O)(C1-C6) haloalkyl, S(O)2(C1-C6 ) haloalkyl, (C1-C6) alkyl-S(O)2NH2 and (C1-C6) haloa selected from the group consisting of alkyl-S(O)2NH2; R 15 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) Alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy(C1-C6) alkyl alkyl, C(=O)(C1-C6) alkyl and (C1-C6) alkoxyC(=O)( C1-C6) alkyl.

[0269] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C2-C6) alkenyl (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkynyl (C2-C6)haloalkenyl and (C1-C6)haloalkoxy; Selected; R 4 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, ( (C1-C6) haloalkyl, (C2-C6) haloalkenyl, (C1-C6) haloalco selected from the group consisting of: R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0270] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 3 is H, F, Cl, Br, I, (C1-C6) alkyl, (C1-C6) alkoxy Selected from the group consisting of (C1-C6)haloalkyl and (C1-C6)haloalkoxy be; R 4 is H, F, Cl, Br, I, CN, (C1-C6) alkyl, (C2-C6) alkyl alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo selected from the group consisting of alkyl and (C2-C6)haloalkenyl; R 13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R 15 is selected from the group consisting of H, CH3 and CF3.

[0271] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 3 is H, F, Cl, Br, I, (C1-C6) haloalkyl and (C1-C6) halo selected from the group consisting of alkoxy; R 4 is H, F, Cl, Br, (C1-C6) alkyl and (C1-C6) haloalkyl selected from the group consisting of: R 13 is Cl or F; R 14 is selected from the group consisting of H and F; R 15 is selected from the group consisting of H and CH3.

[0272] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 is selected from the group consisting of H, F, Cl, Br; R 3 is selected from the group consisting of H, F, Cl, Br and I; R 4 is selected from the group consisting of H, F, Cl, Br; R 13 is Cl; R 14 is H; R 15 is H.

[0273] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 , R 3 , R 4 , R 13 , R 14 , R 15 is defined elsewhere in this specification It is defined as follows.

[0274] In one embodiment of the present invention and / or its embodiments, the present invention provides a compound of formula (XIII) [ka] and N-oxides, veterinarily acceptable acid addition salts, and salt derivatives thereof. Targeting compounds, solvates, ester derivatives, crystalline polymorphs, isotopes, stereoisomers and tautomers year, Here, in the above formula, R 2 are H, F, Cl, Br, I, CN, NH2, NO2, (C1-C6) alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl alkynyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)halo alkyl, (C3-C6) halocycloalkyl, (C2-C6) haloalkenyl, (C3- C6) halocycloalkenyl, (C1-C6) haloalkoxy, S(C1-C6) alkyl S(O)(C1-C6) alkyl, S(O)2(C1-C6) alkyl, S(C1- C6) hal...

Claims

1. In the manufacture of a medicament for treating or controlling a parasitic infestation in an animal, 【Chemistry 1】 [During the ceremony, A １ is CR ５ , where N=O or N; A ２ is CR ６ , where N=O or N; A ３ is CR ７ , where N=O or N; A ４ is CR ８ , where N=O or N; A ５ is CR ９ , where N=O or N; Here, A １ , A ２ , A ３ , A ４ , A ５ of which not more than 3 are N or N=O; R １ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ selected from the group consisting of: R ２ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ and S-(halo) ５ selected from the group consisting of: R ３ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ and S-(halo) ５ selected from the group consisting of: R ４ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ and S-(halo) ５ selected from the group consisting of: R ５ are H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO ２ , O.H., N.H. ２ , =O, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkylphenyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ , (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) cycloalkenyl, (C ３ -C ６ ) cycloalkyl, (C ３ -C ６ ) halocycloalkenyl, (C ３ -C ６ ) halocycloalkyl, (C １ -C ６ ) alkyl ((C １ -C ６ ) alkyl) (= NO(C １ -C ６ ) alkyl), C(=NO(C １ -C ６ ) alkyl) (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl, C(=O)NH(C １ -C ６ ) alkyl, C(=O)NH phenyl, C(=O)O(C １ -C ６ ) alkyl, CH(=NO(C １ -C ６ ) alkyl), imidazolyl, N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl-O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) haloalkyl), N((C １ -C ６ ) alkyl) (C(=O)O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) ２ , N(C(=O)O(C １ -C ６ ) alkyl) ２ , N=CH-phenyl, NH((C １ -C ６ ) alkylC(=O)(C １ -C ６ ) alkyl), NHC(=O)R １０ , N(C １ -C ６ ) alkyl-C(=O)lR １０ , NH(C １ -C ６ ) alkyl, NH(C １ -C ６ ) alkenyl, NH(C １ -C ６ ) alkynyl, NH(C １ -C ６ ) alkylphenyl, NH(S(O) ２ (C １ -C ６ ) alkyl), NH-C(=O)O(C １ -C ６ ) alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C １ -C ６ ) alkyl), S(C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(=NCN)((C １ -C ６ ) alkyl), S(O)(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) selected from the group consisting of haloalkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) haloalkyl, NHCH ２ (C ３ -C ６ ) cycloalkyl, NH ２ , NO ２ , oxo, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkyl, (C １ -C ６ )alkoxy and C(═O)O—(C １ -C ６ ) alkyl; R ６ are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO ２ , O.H., N.H. ２ , =O, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkylphenyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ , (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) cycloalkenyl, (C ３ -C ６ ) cycloalkyl, (C ３ -C ６ ) halocycloalkenyl, (C ３ -C ６ ) halocycloalkyl, (C １ -C ６ ) alkyl ((C １ -C ６ ) alkyl) (= NO(C １ -C ６ ) alkyl), C(=NO(C １ -C ６ ) alkyl) (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl, C(=O)NH(C １ -C ６ ) alkyl, C(=O)NH phenyl, C(=O)O(C １ -C ６ ) alkyl, CH(=NO(C １ -C ６ ) alkyl), imidazolyl, N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl-O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) haloalkyl), N((C １ -C ６ ) alkyl) (C(=O)O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) ２ , N(C(=O)O(C １ -C ６ ) alkyl) ２ , N=CH-phenyl, NH((C １ -C ６ ) alkylC(=O)(C １ -C ６ ) alkyl), NHC(=O)R １０ , N(C １ -C ６ ) alkyl-C(=O)lR １０ , NH(C １ -C ６ ) alkyl, NH(C １ -C ６ ) alkenyl, NH(C １ -C ６ ) alkynyl, NH(C １ -C ６ ) alkylphenyl, NH(S(O) ２ (C １ -C ６ ) alkyl), NH-C(=O)O(C １ -C ６ ) alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C １ -C ６ ) alkyl), S(C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(=NCN)((C １ -C ６ ) alkyl), S(O)(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) selected from the group consisting of haloalkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) haloalkyl, NHCH ２ (C ３ -C ６ ) cycloalkyl, NH ２ , NO ２ , oxo, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkyl, (C １ -C ６ )alkoxy and C(═O)O—(C １ -C ６ ) alkyl; R ７ are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO ２ , O.H., N.H. ２ , =O, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkylphenyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ , (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) cycloalkenyl, (C ３ -C ６ ) cycloalkyl, (C ３ -C ６ ) halocycloalkenyl, (C ３ -C ６ ) halocycloalkyl, (C １ -C ６ ) alkyl ((C １ -C ６ ) alkyl) (= NO(C １ -C ６ ) alkyl), C(=NO(C １ -C ６ ) alkyl) (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl, C(=O)NH(C １ -C ６ ) alkyl, C(=O)NH phenyl, C(=O)O(C １ -C ６ ) alkyl, CH(=NO(C １ -C ６ ) alkyl), imidazolyl, N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl-O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) haloalkyl), N((C １ -C ６ ) alkyl) (C(=O)O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) ２ , N(C(=O)O(C １ -C ６ ) alkyl) ２ , N=CH-phenyl, NH((C １ -C ６ ) alkylC(=O)(C １ -C ６ ) alkyl), NHC(=O)R １０ , N(C １ -C ６ ) alkyl-C(=O)lR １０ , NH(C １ -C ６ ) alkyl, NH(C １ -C ６ ) alkenyl, NH(C １ -C ６ ) alkynyl, NH(C １ -C ６ ) alkylphenyl, NH(S(O) ２ (C １ -C ６ ) alkyl), NH-C(=O)O(C １ -C ６ ) alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C １ -C ６ ) alkyl), S(C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(=NCN)((C １ -C ６ ) alkyl), S(O)(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) selected from the group consisting of haloalkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) haloalkyl, NHCH ２ (C ３ -C ６ ) cycloalkyl, NH ２ , NO ２ , oxo, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkyl, (C １ -C ６ )alkoxy and C(═O)O—(C １ -C ６ ) alkyl; R ８ are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO ２ , O.H., N.H. ２ , =O, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkylphenyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ , (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) cycloalkenyl, (C ３ -C ６ ) cycloalkyl, (C ３ -C ６ ) halocycloalkenyl, (C ３ -C ６ ) halocycloalkyl, (C １ -C ６ ) alkyl ((C １ -C ６ ) alkyl) (= NO(C １ -C ６ ) alkyl), C(=NO(C １ -C ６ ) alkyl) (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl, C(=O)NH(C １ -C ６ ) alkyl, C(=O)NH phenyl, C(=O)O(C １ -C ６ ) alkyl, CH(=NO(C １ -C ６ ) alkyl), imidazolyl, N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl-O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) haloalkyl), N((C １ -C ６ ) alkyl) (C(=O)O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) ２ , N(C(=O)O(C １ -C ６ ) alkyl) ２ , N=CH-phenyl, NH((C １ -C ６ ) alkylC(=O)(C １ -C ６ ) alkyl), NHC(=O)R １０ , N(C １ -C ６ ) alkyl-C(=O)lR １０ , NH(C １ -C ６ ) alkyl, NH(C １ -C ６ ) alkenyl, NH(C １ -C ６ ) alkynyl, NH(C １ -C ６ ) alkylphenyl, NH(S(O) ２ (C １ -C ６ ) alkyl), NH-C(=O)O(C １ -C ６ ) alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C １ -C ６ ) alkyl), S(C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(=NCN)((C １ -C ６ ) alkyl), S(O)(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) selected from the group consisting of haloalkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) haloalkyl, NHCH ２ (C ３ -C ６ ) cycloalkyl, NH ２ , NO ２ , oxo, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkyl, (C １ -C ６ )alkoxy and C(═O)O—(C １ -C ６ ) alkyl; R ９ are F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO ２ , O.H., N.H. ２ , =O, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkylphenyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ , (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) cycloalkenyl, (C ３ -C ６ ) cycloalkyl, (C ３ -C ６ ) halocycloalkenyl, (C ３ -C ６ ) halocycloalkyl, (C １ -C ６ ) alkyl ((C １ -C ６ ) alkyl) (= NO(C １ -C ６ ) alkyl), C(=NO(C １ -C ６ ) alkyl) (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl, C(=O)NH(C １ -C ６ ) alkyl, C(=O)NH phenyl, C(=O)O(C １ -C ６ ) alkyl, CH(=NO(C １ -C ６ ) alkyl), imidazolyl, N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) alkyl-O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) (C(=O) (C １ -C ６ ) haloalkyl), N((C １ -C ６ ) alkyl) (C(=O)O(C １ -C ６ ) alkyl), N((C １ -C ６ ) alkyl) ２ , N(C(=O)O(C １ -C ６ ) alkyl) ２ , N=CH-phenyl, NH((C １ -C ６ ) alkylC(=O)(C １ -C ６ ) alkyl), NHC(=O)R １０ , N(C １ -C ６ ) alkyl-C(=O)lR １０ , NH(C １ -C ６ ) alkyl, NH(C １ -C ６ ) alkenyl, NH(C １ -C ６ ) alkynyl, NH(C １ -C ６ ) alkylphenyl, NH(S(O) ２ (C １ -C ６ ) alkyl), NH-C(=O)O(C １ -C ６ ) alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((C １ -C ６ ) alkyl), S(C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(=NCN)((C １ -C ６ ) alkyl), S(O)(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) selected from the group consisting of haloalkyl, SCN, thiazolyl, thienyl and triazolyl; Here, each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl and triazolyl are F, Cl, Br, I, CN, OH, NH(C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) alkyl, NH(C ３ -C ６ ) CycloalkylCH ２ O (C １ -C ６ ) haloalkyl, NHCH ２ (C ３ -C ６ ) cycloalkyl, NH ２ , NO ２ , oxo, (C １ -C ６ ) alkyl, (C １ -C ６ ) alkyl, (C １ -C ６ )alkoxy and C(═O)O—(C １ -C ６ ) alkyl; Or, R ６ and R ７ together with the atom to which they are attached form a ring containing 5 or 6 atoms, where the atoms forming the ring are -CH ２ -, -CH=, =CH-, -N=, =N-, -NH-, -O-, -S(O)-, -S(O) ２ - and -S-, where R ６ and R ７ The ring formed by (C １ -C ３ ) Alkyl, F, Cl, Br, I, CN, NO ２ and ═O; Or, R ７ and R ８ together with the atom to which they are attached form a ring containing 5 or 6 atoms, where the atoms forming the ring are -CH ２ -, -CH=, =CH-, -N=, =N-, -NH-, -O-, -S(O)-, -S(O) ２ - and -S-, where R ７ and R ８ The ring formed by (C １ -C ３ ) Alkyl, F, Cl, Br, I, CN, NO ２ and ═O; R １０ is H, (C １ -C ６ ) alkyl, C ３ -C ６ ) cycloalkyl), (C １ -C ６ ) alkyloxy-(C １ -C ６ )-alkyl, (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyloxy-(C １ -C ６ ) haloalkyl, C １ -C ６ ) alkyloxy-(C ２ -C ６ )-alkenyl, (C １ -C ６ ) alkyl-(C ３ -C ６ ) cycloalkyl, heterocycle, aryl and (C １ -C ６ ) alkylphenyl; R １１ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ selected from the group consisting of: R １２ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ selected from the group consisting of: R １３ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , CHO, (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ , (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ and triazolyl; R １４ is H, F, Cl, Br, I, CN, NH ２ , NO ２ , (C １ -C ６ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ２ -C ６ ) alkenyl, (C ３ -C ６ ) cycloalkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) haloalkyl, (C ３ -C ６ ) halocycloalkyl, (C ２ -C ６ ) haloalkenyl, (C ３ -C ６ ) halocycloalkenyl, (C １ -C ６ ) haloalkoxy, S(C １ -C ６ ) alkyl, S(O)(C １ -C ６ ) alkyl, S(O) ２ (C １ -C ６ ) alkyl, S(C １ -C ６ ) haloalkyl, S(O)(C １ -C ６ ) haloalkyl, S(O) ２ (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkyl-S(O) ２ N.H. ２ And (C １ -C ６ ) haloalkyl-S(O) ２ N.H. ２ selected from the group consisting of: R １５ is H, (C １ -C ６ ) alkyl, (C ２ -C ６ ) alkenyl, (C ２ -C ６ ) alkynyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) Alkoxy (C １ -C ６ ) alkyl, C(=O)(C １ -C ６ ) alkyl and (C １ -C ６ ) AlkoxyC(=O)(C １ -C ６ ) alkyl; Here, R ５ , R ６ , R ７ , R ８ , R ９ at least one of which is a substituent selected from the group consisting of F, Cl, Br and I. or an N-oxide, veterinarily acceptable acid addition salt, salt derivative, solvate, ester derivative, crystalline polymorph, isotope, stereoisomer or tautomer thereof.

2. R ５ , R ６ , R ７ , R ８ , R ９ The use according to claim 1, wherein at least two of are substituents selected from the group consisting of F, Cl, Br and I, more preferably are substituents selected from F or Cl.

3. A １ , A ２ , A ３ , A ４ , A ５ One of the groups is N, and preferably A １ Or A ２ The use according to any of the preceding claims, wherein is N.

4. R １２ are H, F, CL, and CH ３ , C.F. ３ 2. The use according to any of the preceding claims, wherein the compound is selected from the group consisting of:

5. R １３ is H, F, Cl, CF ３ and C.H. ３ 2. The use according to any of the preceding claims, wherein the compound is selected from the group consisting of:

6. R １５ is H and CH ３ 2. The use according to any of the preceding claims, wherein the compound is selected from the group consisting of:

7. At least one of the following options is performed: R １ is selected from the group consisting of H, F and Cl; and / or R ２ is selected from the group consisting of H, F and Cl; and / or R ３ is selected from the group consisting of H, F and Cl; and / or R ４ is selected from the group consisting of H, F and Cl; 2. Use according to any of the preceding claims.

8. At least one of the following options is performed: R ５ is selected from the group consisting of H, F, Cl, Br and I; and / or R ６ is H, F and Cl, Br and CH ３ and / or R ７ is selected from the group consisting of H, F, Cl, Br and I; and / or R ８ is H, F, Cl, Br and CH ３ and / or R ９ is selected from the group consisting of H, F, Cl, Br and I; 2. Use according to any of the preceding claims.

9. R １ is selected from the group consisting of H, F and Cl; R ２ is selected from the group consisting of H, F and Cl; R ３ is selected from the group consisting of H, F and Cl; R ４ is selected from the group consisting of H, F and Cl; R ５ is selected from the group consisting of H, F, Cl, Br and I; R ６ is H, F and Cl, Br and CH ３ selected from the group consisting of: R ７ is selected from the group consisting of H, F, Cl, Br and I; R ８ is H, F, Cl, Br and CH ３ selected from the group consisting of: R ９ is selected from the group consisting of H, F, Cl, Br and I; R １１ is H; R １２ are H, F, CL, and CH ３ , C.F. ３ selected from the group consisting of: R １３ is H, F, Cl, CF ３ and C.H. ３ selected from the group consisting of: R １４ is H or F; R １５ is H and CH ３ and Here, R ５ , R ６ , R ７ , R ８ , R ９ at least one of is a substituent selected from the group consisting of F, Cl, Br and I; 2. Use according to any of the preceding claims.

10. R １ is H; R ２ is selected from the group consisting of H, F and Cl; R ３ is selected from the group consisting of H, Cl, F and Br; R ４ is H, F, Cl; R ５ is selected from the group consisting of H, F and Cl; R ６ is H, F, Cl and CH ３ selected from the group consisting of: R ７ is selected from the group consisting of H, F and Cl; R ８ is H, F, Cl and CH ３ selected from the group consisting of: R ９ is selected from the group consisting of H, F and Cl; R １１ is H; R １２ is selected from the group consisting of H, F and Cl; R １３ is selected from the group consisting of H, F and Cl; R １４ is H; R １５ is H and CH ３ and Here, R ５ , R ６ , R ７ , R ８ , R ９ at least one of is a substituent selected from the group consisting of F, Cl, Br and I; 2. Use according to any of the preceding claims.

11. 10. The use according to any of the preceding claims, wherein the parasitic infestation is an ectoparasitic infestation.

12. 10. The use according to any of the preceding claims, wherein the parasitic infestation is an acaracide infestation.

13. 10. Use according to any of the preceding claims, wherein the parasitic infestation is an infestation selected from tick, flea and / or fly infestations, preferably an infestation selected from tick infestations.

14. 10. The use according to any of the preceding claims, wherein the parasite is a monohost or multihost tick, preferably the parasite is Rhipicephalus microplus.

15. 10. The use according to any of the preceding claims, wherein the animal is a warm-blooded animal, in particular a mammal.

16. The use according to any of claims 1-15, wherein the animal is a livestock animal, in particular a ruminant, in particular an animal of the bovine subfamily, in particular a cow.

17. The use according to any one of claims 1 to 15, wherein the animal is a fish and the parasitic infestation is a sea lice infestation.

18. The use according to any of claims 1 to 15, wherein the animal is a companion animal, in particular a canine or feline, in particular a dog or a cat.

19. 10. The use according to any of the preceding claims, wherein the animal is protected from infestation by parasites.

20. 10. The use according to any preceding claim, wherein an existing parasitic infestation of the animal is treated or controlled.

21. 10. The use according to any of the preceding claims, wherein the method comprises administering the compound to the animal once per week, once per two weeks, once per month, once per six weeks, once per two months, once per three months, once per six months or once per nine months.

22. In the manufacture of a medicament for treating or controlling a parasitic infestation in an animal, 【Chemistry 2】 or an N-oxide, veterinarily acceptable acid addition salt, salt derivative, solvate, ester derivative, crystalline polymorph, isotope, stereoisomer or tautomer thereof, wherein the compound is 【Table 1】 The use of any one of the following:

23. A veterinary composition comprising an effective amount of a compound of formula (I) as defined in any one of claims 1-10 or 22 and an inert carrier or formulation auxiliary.

24. 24. The veterinary composition of claim 23, wherein the veterinary composition is a topical composition, an oral composition or an injectable composition.

25. 25. A veterinary composition according to claim 23 or 24 and a pharma- ceutically acceptable oily carrier.

26. 26. The veterinary composition of claim 25, wherein the oily carrier comprises, and preferably consists essentially of, a fatty acid ester.

27. The fatty acid ester is ８－１０ 27. The veterinary pharmaceutical composition according to claim 26, which is a glycol diester or glycerol triester of a fatty acid, preferably propylene glycol octanoate decanoate (e.g. Miglyol 840).

28. 26. The veterinary pharmaceutical composition of claim 25, wherein the oil carrier comprises a combination of glycerol monocaprylate and propylene glycol dicaprylocaprate.

29. A veterinary pharmaceutical composition according to any one of claims 23 to 28, wherein the composition does not comprise a penetration enhancer.

30. (a) about 0.5% w / v to about 10% w / v, preferably 1%, of a compound of formula (I); (b1) about 90% w / v to 99.9% w / v, preferably propylene glycol octanoate decanoate; or, alternatively, (b2) about 10% w / v to about 40% w / v, preferably 20%, of glycerol monocaprylate; and (c) optionally propylene glycol dicaprylocaprate, from about 2% w / v to about 50% w / v, preferably 99%; A veterinary pharmaceutical composition according to any one of claims 23 to 29, comprising:

Images